Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9218MR)

This product GTTS-WQ9218MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ9218MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15859MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ6996MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ10954MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ10425MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ5329MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ12616MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ4259MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ7701MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEXMab73
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW